FIELD: medicine; endocrinology.
SUBSTANCE: invention refers to treatment pancreatic diabetes and related complications. Invention implies that method includes introduction of insulin susceptibility intensifier (excepting throglytasone) combined with one agent of group including inhibitor of aldose reductase, byhuanide, statin compounds, squalen synthesis inhibitor, fibrate compound, low-density lipoprotein (LDL) catabolism intensifier and angiotensin converting enzyme inhibitor.
EFFECT: lowered complication risk.
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION | 1996 |
|
RU2198682C2 |
| PHARMACEUTICAL COMPOSITION | 1996 |
|
RU2323004C2 |
| METHODS FOR PROPHYLAXIS AND TREATMENT, APPLICATION OF AGENT TO ENHANCE INSULIN SUSCEPTIBILITY | 2003 |
|
RU2286148C2 |
| METHOD FOR PROPHYLAXIS AND TREATMENT, USING ENHANCER FOR INSULIN SENSIBILITY | 1996 |
|
RU2223760C2 |
| PANCREATIC DIABETES DRUG | 2004 |
|
RU2358738C2 |
| METHOD FOR TREATMENT OF IMPAIRED GLUCOSE TOLERANCE | 2001 |
|
RU2281094C2 |
| PHARMACEUTICAL COMPOSITIONS | 2010 |
|
RU2532330C2 |
| APPLICATION OF THIAZOLIDINEDIONES FOR PREVENTION OR ONSET POSTPONEMENT OF INSULIN-INDEPENDENT DIABETES MELLITUS (NIDDM) | 1994 |
|
RU2195282C2 |
| THERAPEUTIC ANTIDIABETIC AGENT | 2006 |
|
RU2438671C2 |
| CONDENSED HETEROCYCLIC DERIVATIVES MEDICAL COMPOSITIONS CONTAINING THEM AND THEIR MEDICAL APPLICATION | 2005 |
|
RU2387663C2 |
